Cullinan Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Cullinan Therapeutics es Nadim Ahmed , nombrado en Oct 2021, tiene una permanencia de 3.08 años. compensación anual total es $4.01M, compuesta por 16.2% salario y 83.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.045% de las acciones de la empresa, por valor de $320.76K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 1.4 años, respectivamente.

Información clave

Nadim Ahmed

Chief Executive Officer (CEO)

US$4.0m

Compensación total

Porcentaje del salario del CEO	16.2%
Permanencia del CEO	3.1yrs
Participación del CEO	0.05%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	1.4yrs

Actualizaciones recientes de la dirección

Recent updates

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Nov 20

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Aug 30

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Nadim Ahmed en comparación con los beneficios de Cullinan Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$144m
Jun 30 2024	n/a	n/a	-US$142m
Mar 31 2024	n/a	n/a	-US$132m
Dec 31 2023	US$4m	US$649k	-US$153m
Sep 30 2023	n/a	n/a	-US$156m
Jun 30 2023	n/a	n/a	-US$142m
Mar 31 2023	n/a	n/a	US$65m
Dec 31 2022	US$4m	US$618k	US$111m
Sep 30 2022	n/a	n/a	US$105m
Jun 30 2022	n/a	n/a	US$113m
Mar 31 2022	n/a	n/a	-US$78m
Dec 31 2021	US$39m	US$125k	-US$66m

Compensación vs. Mercado: La compensación total ($USD4.01M) de Nadim está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.19M).

Compensación vs. Ingresos: La compensación de Nadim ha aumentado mientras la empresa no es rentable.

CEO

Nadim Ahmed (56 yo)

3.1yrs

Permanencia

US$4,008,206

Compensación

Mr. Nadim Ahmed has been a President, Chief Executive Officer and Director of Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since October 18, 2021. He joined Cullinan Therapeutics...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nadim Ahmed	President	3.1yrs	US$4.01m	0.045% $ 320.8k
Jeffrey Jones	Chief Medical Officer	2.8yrs	US$2.42m	0.024% $ 167.3k
Patrick Baeuerle	Co-Founder	no data	US$1.96m	0.61% $ 4.3m
Mary Fenton	Chief Financial Officer	less than a year	sin datos	sin datos
Jennifer Michaelson	Chief Scientific Officer	1.4yrs	sin datos	0.045% $ 317.5k
Jacquelyn Sumer	Chief Legal Officer	2.3yrs	sin datos	0.017% $ 120.5k
Rose Weldon	Senior Vice President of Communications	2.8yrs	sin datos	sin datos
Steve Andre	Chief Human Resources Officer	2.8yrs	sin datos	sin datos
Corinne Savill	Chief Business Officer	7.8yrs	sin datos	0.25% $ 1.7m
Kevin Johnston	Chief Technical Operations Officer	2.8yrs	sin datos	sin datos

2.8yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CGEM se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nadim Ahmed	President	3.1yrs	US$4.01m	0.045% $ 320.8k
Patrick Baeuerle	Co-Founder	1.4yrs	US$1.96m	0.61% $ 4.3m
Stephen Webster	Independent Director	4.2yrs	US$232.24k	0% $ 0
Anthony Rosenberg	Independent Chairman of the Board	7.3yrs	US$284.84k	0.077% $ 550.0k
Ronald Levy	Member of Scientific Advisory Board	1.4yrs	sin datos	sin datos
Anthony Tolcher	Member of Scientific Advisory Board	1.4yrs	sin datos	sin datos
Bahija Jallal	Member of Scientific Advisory Board	1.4yrs	sin datos	sin datos
David Meek	Independent Director	less than a year	sin datos	sin datos
Anne-Marie Martin	Independent Director	2.7yrs	US$164.45k	0% $ 0
Patricia LoRusso	Member of Scientific Advisory Board	1.4yrs	sin datos	sin datos
David Ryan	Independent Director	2yrs	US$43.75k	0% $ 0
David McDermott	Member of Scientific Advisory Board	1.4yrs	sin datos	sin datos

1.4yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de CGEM no se considera experimentada (1.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Cullinan Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Chief Scientific Officer notifies of intention to sell stock

Independent Director exercised options to buy US$402k worth of stock.

Independent Director exercised options to buy US$2.4m worth of stock.

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Recent updates

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024

Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Chief Scientific Officer notifies of intention to sell stock

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors

Investor sentiment improved over the past week

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology grants stock options for 125.7K shares

Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal Officer

Insider recently sold US$712k worth of stock

Chief Business Officer notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth Index

Insider recently sold US$1.3m worth of stock

Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

President recently bought US$100k worth of stock

Insider recently sold US$4.0m worth of stock

Price target decreased to US$39.25

Forecast to breakeven in 2022

Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.

Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology, Inc. to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio At American Association for Cancer Research 2022

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology, Inc. Announces Management Appointments

Price target decreased to US$47.75

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Cln-081 for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Strategic Advisor notifies of intention to sell stock

Cullinan Oncology, Inc. Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CFO & Treasurer exercised options and sold US$166k worth of stock

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth